24 results about "Liver triglyceride" patented technology

The invention relates to the technical field of biotechnology and gene function and application, and provides application of SNHG8 in preparation of drugs for preventing and treating non-alcoholic fatty liver diseases. The medicine is used for preventing and treating the non-alcoholic fatty liver disease by promoting SNHG8 gene expression. The SNHG8 is applied to preparation of the medicine for preventing and treating the non-alcoholic fatty liver disease, the medicine can effectively reduce the content of triglyceride in the liver by promoting SNHG8 gene expression, liver lipid accumulation increase and lipid metabolism related protein expression up-regulation induced by high-fat and high-cholesterol diet are relieved, and therefore the non-alcoholic fatty liver disease is prevented, treated or relieved. The purpose of preventing and treating the non-alcoholic fatty liver disease is achieved.

The invention belongs to the technical field of biological medicines, and provides application of alnulone and analogues thereof in prevention and treatment of fatty liver diseases and auxiliary blood fat reduction. The invention also provides a composition for treating fatty liver diseases or assisting in reducing blood fat. The composition comprises an effective dose of alnulone and analogues thereof. The alnnulone and the analogue thereof provided by the invention have the effects of reducing blood triglyceride and liver triglyceride and reversing liver fatty degeneration in vivo, can improve liver fibrosis and inflammation symptoms of a mouse with steatohepatitis, and are good in safety, free of toxic and side effects and free of toxic and side effects. The compound can be used for preparing medicines for preventing and treating fatty liver diseases, steatohepatitis and related diseases.

The invention provides vinasse dietary fiber with blood fat reducing activity and a preparation method of the vinasse dietary fiber. The vinasse dietary fiber with relatively high purity is obtained by performing alkali soaking, sodium chlorite bleaching, crushing and drying on the vinasse. The prepared vinasse dietary fiber can effectively improve hyperlipidemia of obese diabetes model mice, reduce triglyceride and total cholesterol levels of serum and liver and improve liver injury, and can be applied to preparation of functional food, health care products, medicines and feeds with the blood glucose reducing effect.

The present invention belongs to the field of biomedical technology and provides an application of betulinone and its analogs in the prevention and treatment of fatty liver disease and adjuvant lipid-lowering. The present invention also provides a composition for treating fatty liver disease or adjuvant lipid-lowering, which comprises an effective dose of betulinone and its analogs. The betulinone and its analogs provided by the present invention have the effects of reducing blood triglyceride and liver triglyceride in vivo, reversing liver steatosis, and can improve liver fibrosis and inflammatory symptoms of mice with fatty hepatitis, and have good safety and no toxic side effects, and can be used for preparing preventive and therapeutic drugs for fatty liver disease, fatty hepatitis and related diseases.

The present application provides a polypeptide composition with anti-obesity effect, which is composed of capsaicin and polypeptides, and the amino acid sequence of the polypeptides comprises any one or more of SEQ ID NO. 1 to SEQ ID NO. 8. The polypeptides of sequences 1-8 are mixed uniformly at a mass ratio of 1-20:1-4:1-2:1-4:1:1:1:1, and the capsaicin is mixed with the mixed polypeptides at a ratio of 2-12:100 (w / w). The polypeptide composition proposed in the present application, in combination with capsaicin, not only promotes the weight loss effect of capsaicin, but also significantly reduces the fat index of the test mice after use, and can significantly reduce the total cholesterol concentration in the liver and the liver triglyceride concentration under a high-fat diet.

The invention discloses an adeno-associated virus overexpressing GPR110 and application of the adeno-associated virus in preparation of a medicine for treating metabolism-related steatohepatitis. The adeno-associated virus comprises a GPR110 gene sequence encoded and operably connected to a liver specific promoter TBG, an in-vivo experiment is carried out in a constructed MASH mouse model, and the result shows that the expression of the GPR110 gene in the liver tissue of the MASH mouse model is reduced, so that the GPR110 gene can be used as a biomarker and a therapeutic target of MASH, and the application of the GPR110 gene in the MASH mouse model is proven. According to the present invention, the MASH-related symptoms can be significantly improved through the AAV adeno-associated virus targeting liver specific overexpression GPR110, wherein the MASH-related symptoms comprise liver triglyceride content reducing, liver injury relieving, liver inflammation improving and liver fibrosis improving; the AAV-mediated GPR110 overexpression can effectively improve the MASH pathological process, and new intervention drugs and means can be provided for MASH treatment.

The invention relates to the technical field of poultry health assessment, in particular to a method for predicting and identifying the high fat deposition risk of the liver of a laying hen based on blood amino acid parameters. The method comprises the following steps: collecting a blood sample when the laying hen is in a metabolic state after absorption, detecting the total amino acid content and the alanine content in blood, and substituting blood parameters into a pre-established liver triglyceride prediction model to obtain the predicted liver triglyceride content, and comparing the prediction results to judge the high fat deposition risk of the liver of the laying hen. According to the method, the laying hens do not need to be slaughtered and sampled, the fat deposition state of the livers of the living laying hens can be rapidly evaluated, and the method is suitable for early screening and risk early warning of high fat deposition of the livers of the laying hens under the large-scale breeding condition.

The application belongs to the technical field of biological medicine, and provides application of THADA in hyperlipidemia and cardiovascular metabolic diseases. THADA is used as a biomarker or target to prepare reagents for disease prediction, screening or diagnosis, and to prepare drugs for preventing or treating diseases. Inhibition or destruction of THADA function has the purposes of reducing blood cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, not affecting high-density cholesterol levels, reducing liver triglyceride deposition and liver steatosis, and improving atherosclerosis, and the effect is clear and effective and has no adverse reactions. The application provides a new biomarker and treatment target for hyperlipidemia and cardiovascular metabolic diseases, and has good practical application value and wide application prospect.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

The invention belongs to the technical field of biological medicine, and provides application of THADA in hyperlipidemia and cardiovascular metabolic diseases. THADA as a biomarker or a target can be used for preparing a reagent for predicting, screening or diagnosing diseases and preparing a medicine for preventing or treating the diseases. The traditional Chinese medicine composition has the functions of reducing blood cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels in vivo, not influencing the high-density cholesterol level, reducing liver triglyceride deposition and liver fatty degeneration and improving atherosclerosis, the effect is definite and effective, and no adverse reaction exists. The invention provides a new biomarker and a treatment target for hyperlipidemia and cardiovascular metabolic diseases, and has good practical application value and wide application prospect.

The invention discloses an application of Pantoea ananatis, and relates to the technical field of microorganisms. Aiming at the defects of the existing obesity intervention means, the invention provides a brand-new solution: Pantoea anatitis adapted to a high-altitude environment is used as a core functional strain, through an intestinal flora driving mechanism, the expression of UCP1 protein in brown adipose tissue (BAT) is activated, the heat production function of the BAT is enhanced, and meanwhile, the storage of white adipose tissue (WAT) and the level of liver triglyceride (TG) are reduced; the weight-losing effect is realized. The strain can play a role through an'intestinal flora-BAT 'axis without cold exposure, has no obvious influence on liver functions, and is excellent in safety. The invention discloses a flora-mediated non-cold-dependent BAT activation way for the first time, can be used for preparing products such as weight-reducing medicines and health-care foods, has the advantages of mechanism innovation, exact effect and wide application, and provides a new technical choice for obesity intervention.

The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of antisense oligonucleotide small molecules in preparation of medicines for improving fatty liver. The antisense oligonucleotide small molecule is GalNAC-APJASO, and the GalNAC-APJASO is obtained after the 3'tail end of APJASO is subjected to GalNAC coupling modification, and the 3 'tail end of APJASO is subjected to GalNAC coupling modification. The base sequence of the APJ ASO is as shown in SEQ ID NO. 1. In-vivo experiments prove that the GalNAC-APJASO has a positive treatment effect on the non-alcoholic fatty liver disease, and particularly, the GalNAC-APJASO obviously improves the symptoms of the non-alcoholic fatty liver disease of mice, improves the glucose tolerance and insulin tolerance of the mice, improves the fatty degeneration of the liver, reduces the lipid accumulation of the liver, reduces the triglyceride level of the liver and inhibits fat cell hypertrophy, so that the GalNAC-APJASO can be used for treating the non-alcoholic fatty liver disease of the mice. A candidate medicine is provided for treating the non-alcoholic fatty liver disease and related symptoms thereof. In addition, the GalNAC-APJASO specifically targets the liver tissue, compared with existing drugs for treating the non-alcoholic fatty liver disease, toxic and side effects are smaller, and compared with the prior art, remarkable progress is achieved.

The invention provides an application of Importazole in obesity, and belongs to the technical field of biological medicines. The invention provides an application of Importazole (IPZ) in preparation of drugs for treating obesity and / or obesity-related metabolic syndromes, when IPZ is used for treating obese mice, the weight of the mice is reduced, and the values of fasting blood-glucose, serum triglyceride, cholesterol and liver triglyceride are obviously reduced, so that the method has a good treatment effect on obesity and the obesity-related metabolic syndromes. In addition, in the administration period, mice do not have obvious adverse reactions or side effects, and it is indicated that the method has high safety.

The present invention provides Lactobacillus plantarum ZJUIDS14 and its application for improving non-alcoholic liver disease, which is classified and named as: Lactiplantibacillus plantarum, and the preservation number is: CGMCC NO.28091. The strain of the present invention regulates the abundance of various intestinal probiotics in the intestine and promotes the synthesis of intestinal short-chain fatty acids to restore the intestinal barrier function damaged by a high-fat diet. In addition, ZJUIDS14 and the extracellular polysaccharides produced by it can inhibit the liver fatty acid synthesis pathway to reduce liver triglyceride deposition, and improve liver damage through antioxidant pathways. The strain has the functions of protecting liver damage, improving antioxidant effects in the body, reducing liver triglycerides, reducing liver fatty acid synthesis, restoring intestinal barrier function, promoting intestinal short-chain fatty acid synthesis, and improving intestinal flora, and can be used in the preparation of functional foods such as bacterial powder, yogurt or milk powder.

The invention provides application of clofarabine in obesity treatment, and belongs to the technical field of biological medicines. The invention provides the application of clofarabine in obesity treatment, and a new thought can be provided for obesity treatment. An obese mouse model is utilized, clofarabine is used for treating an obese mouse, the weight of the obese mouse is reduced, and the values of fasting blood-glucose, serum triglyceride, cholesterol and liver triglyceride are obviously reduced, so that clofarabine has a good treatment effect on obesity and related metabolic syndromes. Meanwhile, in the administration period, mice do not have obvious adverse reactions or side effects, which indicates that the clofarabine has high safety.

The invention provides application of a specific dihydroquinoline derivative in preparation of a product for preventing or treating fatty liver. It is found for the first time that the specific dihydroquinoline derivative significantly reduces the liver triglyceride level, so that alcohol-induced liver fatty degeneration is relieved, and the dihydroquinoline derivative has a good clinical transformation prospect.

The application provides use of a specific KPNA2 agonist and a combination of the specific KPNA2 agonist and other substances in preparation of a product for preventing or treating fatty liver. It is found for the first time that the specific KPNA2 agonist can significantly reduce liver triglyceride levels, thereby reducing alcohol-induced liver steatosis, and has good clinical conversion prospects, and the combination of the specific KPNA2 agonist and other substances has better effects.

The invention discloses a benzopyrone analogue as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The benzopyrone analogue has a structural formula as shown in a formula B in the specification. The invention also discloses a preparation method and application of the benzopyrone analogue. The invention provides a benzopyrone analogue with a new structure, and the benzopyrone analogue is named as ZDZ-553. The benzopyrone analogue can obviously reduce the content of triglyceride and cholesterol in the liver, also can obviously inhibit the inflammatory reaction of the liver of an NASH mouse, and can obviously reduce the mRNA level of inflammatory factors IL-6, IL-1beta and TNF-alpha in the liver. Therefore, the benzopyrone analogue disclosed by the invention can be used for preparing the medicine for resisting the non-alcoholic steatohepatitis.

The invention provides application of a specific KPNA2 agonist and application of the KPNA2 agonist and other substances in preparation of products for preventing or treating fatty liver. The specific KPNA2 agonist is found for the first time to remarkably reduce the level of liver triglyceride, so that alcohol-induced liver fatty degeneration is relieved, and the KPNA2 agonist has a good clinical transformation prospect and has a better effect when being combined with other substances.

The invention relates to the field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition, a pharmaceutical preparation and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following components in parts by weight: 6-12 parts of eclipta, 3-9 parts of pseudo-ginseng, 6-12 parts of dogwood, 9-15 parts of teasel root, 6-12 parts of grifola, 3-6 parts of felwort, 3-10 parts of polygala tenuifolia, 2-3 parts of hypericum perforatum, 10-30 parts of sedum sarmentosum, 3-9 parts of inula flower, 6-9 parts of curcuma zedoary, 5-10 parts of cowherb seed, 6-12 parts of changium smyrnioides and 9-15 parts of erigeron breviscapus. The traditional Chinese medicine composition can regulate and control non-alcoholic steatohepatitis related signal channels on HepG2, LX2, THP1 and HUVECT1 cell lines, reduce the fat content in a HepG2 cell high-fat model, reduce the serum alanine aminotransferase, serum aspartate aminotransferase, serum low-density lipoprotein cholesterol and liver triglyceride level of a mouse non-alcoholic steatohepatitis model, and improve the non-alcoholic steatohepatitis content in the mouse non-alcoholic steatohepatitis model. The traditional Chinese medicine composition is capable of reducing liver fat accumulation, relieving liver injury and improving liver fibrosis pathology, and is used for related treatment or adjuvant treatment of non-alcoholic steatohepatitis.

The present invention relates to a composition comprising branched-chain amino acid metabolites for use in reducing hepatic triglycerides and / or improving glucose metabolism in an individual.

This invention provides the application of specific dihydroquinoline derivatives in the preparation of products for the prevention or treatment of fatty liver. This invention is the first to discover that specific dihydroquinoline derivatives significantly reduce liver triglyceride levels, thereby alleviating alcohol-induced hepatic steatosis, and possesses promising prospects for clinical translation.

The application relates to the technical field of biotechnology, gene function and application, and provides application of SNHG8 in preparation of a non-alcoholic fatty liver disease prevention and treatment drug. The drug can prevent and treat non-alcoholic fatty liver disease by promoting SNHG8 gene expression. The application of SNHG8 in preparation of the non-alcoholic fatty liver disease prevention and treatment drug can effectively reduce the liver triglyceride content, relieve the increase of liver lipid accumulation and the up-regulation of lipid metabolism related protein expression induced by high-fat and high-cholesterol diet, so as to prevent, treat or relieve non-alcoholic fatty liver disease, and achieve the purpose of preventing and treating non-alcoholic fatty liver disease.

The application discloses application of a Solanum torvum extract in preparation of a medicine for preventing and treating non-alcoholic fatty liver and indications thereof, and the Solanum torvum extract comprises one or both of a Solanum torvum water extract and a Solanum torvum alcohol extract; the application is proved by experiments that the Solanum torvum alcohol extract can obviously reduce the weight of a non-alcoholic fatty liver NAFLD mouse; the Solanum torvum water extract can obviously reduce the inguinal white fat; the Solanum torvum extract can obviously reduce a liver weight / body weight index, a liver triglyceride (TG) content, liver lipid deposition, and liver function damage indexes, i.e., glutamic-oxalacetic transaminase (AST) and glutamic-pyruvic transaminase (ALT). The Solanum torvum extract can also reduce serum triglyceride (TG) and cholesterol (TC) levels of the mouse, improve lipid levels, and therefore has an important role in treating non-alcoholic fatty liver.